



**Description****SUBJECT OF THE INVENTION**

5 [0001] The present invention is directed to amides of hyaluronic acid and derivatives thereof for the preparation of pharmaceutical formulations, of biomaterials and for the coating of biomedical objects and the process for their preparation.

**FIELD OF THE INVENTION**

10 [0002] Hyaluronic acid is a heteropolysaccharide composed of alternate residues of D-glucuronic acid and N-acetyl-D-glycosamine. It is a straight-chained polymer the molecular weight of which varies between 50,000 and 13,000,000 Da depending on the source from which it was obtained and the methods used to obtain it. It is present in nature in pericellular gels, in the fundamental substance of the connective tissue of vertebrate organisms of which it represents

15 one of the main components, in the synovial fluid of the joints, in the vitreous humor, in the human umbilical cord tissues and in rooster combs.

[0003] In recent years, numerous types of hyaluronic acid derivatives have been synthesised to obtain compounds with pharmacological properties, or compounds that can be processed in various forms of biodegradable and biocompatible biomaterials for use in various fields of medicine, surgery and tissue engineering.

20 [0004] Among the amide derivatives reported in the state of the art are known water-insoluble compositions constituted by mixtures deriving from the reaction between the carboxyl of hyaluronic acid, a nucleophil, such as an amine compound, and an activating agent (US 5,760,200; US 4,937,270). Such mixtures are mainly used in the prevention of post-surgical adhesions.

25 [0005] U.S. patent No. 5,733,891 describes pharmaceutical compositions containing amide derivatives of hyaluronic acid obtained by reaction of its carboxyls with basic anti-tumour agents. The purpose of these compounds is to focus the action of the active principle on the diseased tissues and to limit any harmful effects on the healthy tissues.

[0006] Moreover, there are known amides of glycosaminoglycans, such as hyaluronic acid, with photosensitive compounds bound by polyfunctional compounds that act as bridges in the formation of amide bonds (US 5,462,976).

30 [0007] Lastly, there is a known process for the preparation of insoluble amides by the reaction of active esters of hyaluronic acid with amines. (WO 95/24429).

[0008] The aim of the present invention is to provide isolated and characterised amides of hyaluronic acid or derivatives thereof, obtained by reacting the carboxy groups or amino groups originating from deacetylation reactions, with amines and acids of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series respectively, and without the use of spacer chains.

35 [0009] Said compounds can be either water soluble or insoluble, according to the acid, the amine, the percentage of amide bond or the derivative of hyaluronic acid used to prepare the amide.

[0010] Therefore, the products according to the present invention are suitable for a large number of applications according to their solubility in water, their viscosity and the stability of the amide bond.

40 [0011] Indeed, said compounds can be used to prepare both pharmaceutical compositions and biomaterials. Moreover, they have the advantage of being able to be formed by reaction, not only with amines, but also with pharmacologically active acids.


**DETAILED DESCRIPTION OF THE INVENTION**

45 [0012] The present invention is directed to amidic, water-soluble compounds of hyaluronic acid and derivatives thereof for the preparation of pharmaceutical formulations, biomaterials and for the coating of biomedical objects and the process for their preparation.

[0013] The amidic, water-soluble compounds according to the present invention can be represented by the following general formula that represents the repetitive unit of the polymer:

50

55



wherein:

15 R = NR<sub>6</sub>R<sub>7</sub>, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, OH, O-, alcoholic group of hyaluronic acid, amino group of deacylated hyaluronic acid;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, -CO-(CH<sub>2</sub>)<sub>2</sub>-COOY; Y = negative charge, or H;

R<sub>5</sub> = -CO-CH<sub>3</sub>, H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, acyl group of hyaluronic acid;


20 R<sub>6</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or un-substituted;

R<sub>7</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or un-substituted;

25 wherein at least one of R or R<sub>5</sub> forms an amide group,

with the provisos that when R<sub>6</sub> is H, R<sub>7</sub> is not -CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, and that the amidic, water-soluble compound is not combined with a medicinal ingredient through an amide bond.

[0014] In another aspect, the invention concerns pharmaceutical compositions containing amidic water-soluble compounds of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of the following general formula:



wherein:

45 R = NR<sub>6</sub>R<sub>7</sub>, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, OH, O-, alcoholic group of hyaluronic acid, amino group of deacylated hyaluronic acid;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, -CO-(CH<sub>2</sub>)<sub>2</sub>-COOY; Y = negative charge, or H;

50 R<sub>5</sub> = -CO-CH<sub>3</sub>, H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, acyl group of hyaluronic acid;

R<sub>6</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or un-substituted;

R<sub>7</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or un-substituted;

55 wherein at least one of R or R<sub>5</sub> forms an amide group,

alone or in association with one another or with other pharmacologically active substances and in association with a

pharmaceutically acceptable carrier, with the proviso that the amidic, water-soluble compound is not combined with a medicinal ingredient through an amide bond.

[0015] In a further aspect, the invention concerns biomaterials constituted by amidic water-soluble compounds of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of the following general formula:

5

10

15

wherein:

20 R = NR<sub>6</sub>R<sub>7</sub>, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, OH, O-, alcoholic group of hyaluronic acid, amino group of deacylated hyaluronic acid;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, -CO-(CH<sub>2</sub>)<sub>2</sub>-COOY; Y = negative charge, or H;

25 R<sub>5</sub> = -CO-CH<sub>3</sub>, H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, acyl group of hyaluronic acid;

R<sub>6</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or un-substituted;

30 R<sub>7</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or un-substituted;

wherein at least one of R or R<sub>5</sub> forms an amide group, alone or in association with one another or with other natural, semisynthetic, synthetic polymers and, optionally, with biologically active substances, with the proviso that the amidic, water-soluble compound is not combined with a medicinal ingredient through an amide bond.

35

[0016] In yet another aspect, the invention concerns the use of amidic water-soluble compounds of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of the following general formula:

40

45

wherein:

50 R = NR<sub>6</sub>R<sub>7</sub>, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, OH, O-, alcoholic group of hyaluronic acid, amino group of deacylated hyaluronic acid;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, -CO-(CH<sub>2</sub>)<sub>2</sub>-COOY; Y = negative charge, or H;

55 R<sub>5</sub> = -CO-CH<sub>3</sub>, H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, acyl group of hyaluronic acid;

R<sub>6</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or un-substituted;

$R_7$  = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted;

wherein at least one of  $R$  or  $R_5$  forms an amide group

5 with the proviso that the amidic, water-soluble compound is not combined with a medicinal ingredient through an amide bond,

either:

for the preparation of salts with pharmacologically active substances;

or:

10 when alone or in association with one another and/or with pharmacologically active substances for the preparation of pharmaceutical compositions, biomaterials, surgical and health-care articles, slow release systems and systems, for the coating of biomedical objects;

or:

15 when in association with radioactive and non-radioactive substances, used in contrast systems as labels in in vivo diagnostics, for the identification and treatment of tumoral tissues or damaged tissues.

[0017] These are therefore amides obtained by reaction of an amine with a free carboxyl of hyaluronic acid or a derivative thereof, or by reaction of an acid with a deacylated amino group of hyaluronic acid or a derivative thereof.

[0018] Of the hyaluronic acid derivatives that can be used to prepare amides according to the present invention, the following are preferred:

20 - hyaluronic acid esters wherein a part or all of the carboxy functions are esterified with alcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series (EP 0216453 B1);

- autocross-linked esters of hyaluronic acid wherein a part or all of the carboxy groups are esterified with the alcoholic functions of the same polysaccharide chain or other chains (EP 0341745 B1);

25 - the cross-linked compounds of hyaluronic acid wherein a part or all of the carboxy groups are esterified with poly-alcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, generating cross-linking by means of spacer chains (EP 0265116 B1);

- hemiesters of succinic acid or the heavy metal salts of the hemiester of succinic acid with hyaluronic acid or with partial or total esters of hyaluronic acid (WO 96/357207);

30 - the O-sulphated derivatives (WO 95/25751) or N-sulphated derivatives (PCT/EP98/01973).

[0019] Of the amides obtained by reaction of an amine on the carboxyl of hyaluronic acid or of a derivative thereof, of particular interest are the water-soluble ones.

[0020] By amide is meant a group of the formula  $-CON=$ .

35 [0021] Aliphatic means acyclic or pertaining to open-chain or branched carbon compounds such as alkanes, alkenes or alkynes. Examples of an aliphatic moiety include but are not limited to  $C_1-C_{20}$  noncyclic hydrocarbons and their isomers such as methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, isobutyl, pentyl, isopentyl, neopentyl, tert-pentyl, 2-methylbutyl, 1,2-dimethylpropyl, hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, cetyl, heptadecyl, octadecyl, nonadecyl, stearyl, etc.

[0022] Aromatic means an aryl moiety having one or more unsaturated rings, each ring usually having 5 to 8 members and preferably 5 to 6 members. Examples of the aromatic moiety include but are not limited to benzyl, toluyl, naphthyl, anthracenyl, phenanthryl, fluorenyl, coronenyl, triphenylenyl, fluoranthenyl, benzofluoranthenyl, benzopyrenyl, and pyrenyl.

40 [0023] Cycloaliphatic pertains to a carbon ring structure, usually having 3 to 8 members and preferably 5 to 6 members, that does not contain a resonance structure. Examples of cycloaliphatic groups include but are not limited to cycloalkanes and cycloolefins such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclohexenyl (tetrahydrobenzyl), cyclohexylidene, and cyclooctadienyl. The heterocyclic series pertains to dissimilar atoms in a ring. A heterocyclic group is a heteroaryl group usually having a 3- to 8-membered, preferably 5- to 6-membered ring or fused ring containing at least one hetero atom (such as O, S, N, etc.) and include but are not limited to thienyl, furanyl, pyranyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, isothiazolyl, isoxazolyl, furazanyl, benzothienyl, isobenzofuranyl, chromenyl, indolindinyl, isoindolyl, Indolyl, purinyl, quinolidinyl, isoquinolyl, quinolyl, phthalazinyl, quinazolyl, carbazolyl, acridinyl, and phenanthridinyl.

45 [0024] An arylalkyl group is a group having both aromatic and aliphatic substituents as defined above. Examples of arylalkyl groups include but are not limited to ethylbenzyl, isobutylbenzene, benzyl, ethylbenzyl, propylbenzyl, isopropylbenzyl, butylbenzyl, isobutylbenzyl, cyclohexylbenzyl, styrenyl, and biphenyl.

[0025] An acyl group is an organic radical derived from an organic acid by the removal of a hydroxy group. Examples

of acyl groups include but are not limited to formyl, acetyl, propionyl, butyryl, valeryl, isovaleryl, pivaloyl; aroyl such as benzenesufonyl, benzoyl, toluoyl, and naphthoyl; diacyl groups such as oxalyl and succinic anhydride; and heteroaroyls such as furoyl, nicotinoyl, isonicotinoyl, etc:

5 [0026] Such amides can be advantageously used for the preparation of pharmaceutical compositions, for example in the form of gels, for the transport and release of drugs or biologically active substances for use in viscoelastic surgery or in ophthalmic surgery.

10 [0027] The amides according to the present invention can be salified with the heavy metals on the free or sulfuric carboxy groups, meaning by heavy metals the elements of the 4<sup>th</sup>, 5<sup>th</sup> and 6<sup>th</sup> periods of the periodical table such as silver, iron, cobalt, copper, zinc, arsenic, strontium, zirconium, antimony, gold, cesium, tungsten, selenium, platinum, ruthenium, bismuth, tin, titanium and mercury. Said salts can be used in dermatology, in ophthalmology, in dentistry, 15 stomatology, rheumatology, urology, gynaecology, internal surgery, as food supplements, anti-oxidating, anti-rheumatic, anti-tumoural, anti-inflammatory, analgesic and anti-ulcer agents.

[0028] Moreover, the amide derivatives can be obtained by reaction of carboxyl or deacylated nitrogen of hyaluronic acid or a derivative thereof with an amine or with a pharmacologically active acid respectively, or they may be salified 20 or simply associated with said compounds.

[0029] Of the pharmacologically active substances, the following are preferred: antibiotics, anti-infective, antimicrobial, antiviral, cytostatic, cytotoxic, anti-tumoural, anti-inflammatory and wound healing agents, anaesthetics, analgesics, vasoconstrictors, cholinergic or adrenergic agonists and antagonists, anti-thrombotic, anti-coagulant, haemostatic, fibrinolytic and thrombolytic agents, proteins and their fragments, peptides and polynucleotides.

25 [0030] Hereafter we report some examples of pharmacologically active substances belonging to the aforesaid classes of drugs:

- antibiotics: amino glucosides, macrolides, tetracycline, peptides such as gentamicin, neomycin, streptomycin, dihydrostreptomycin, kanamycin, amikacin, tobramycin, spectinomycin, erythromycin, olcandomycin, carbomycin, spiramycin, oxytetracycline, rolitetracycline, bacitracin, polymyxin B, gramicidin, colistin, chloramphenicol, lincomycin, vancomycin, novobiocin, ristocetin, clindamycin, amphotericin B, griseofulvin, nystatin and their salts;
- anti-infective agents: diethylcarbamazine, mebendazole, sulfamides such as sulfacetamide, sulfadiazine, sulfisoxazole;
- anti-virals and anti-tumourals: idoxuridine, adenine, adenine arabinoside, trifluorothymidine, acyclovir, ethyldeoxyuridine, bromovinyldeoxyuridine, 5-ido-5'-amino-2',5'-dideoxyuridine;
- steroid anti-inflammatory agents: dexamethasone, hydrocortisone, prednisolone, fluorometholone, medrysone and their esters;
- non-steroid anti-inflammatory agents: indomethacin, oxyphenbutazone, fluoribuprofen, dichlofenac, ibuprofen;
- anaesthetics: benoxinate, proparacaine, dibucaine, lidocaine, benzocaine, benzylamine, bupivacaine and their salts;
- cholinergic agonists: pilocarpine, methacholine, carbamylcholine, aceclidine, physostigmine, neostigmine, demecarium and their salts;
- cholinergic antagonists: atropine and its salts;
- adrenergic agonists: noradrenalin, adrenalin, naphazoline, methoxamine and their salts;
- adrenergic antagonists: propanolol, timolol, pindolol, bupranolol, athenolol, methoprolol, oxprenolol, practolol, butoxamine, sotalol, butadrine, labetalol and their salts;
- antibacterials and disinfectants: nitrofurazone, mafenide, chlorhexidine, the derivatives of 8-hydroxyquinoline and their salts;
- cytotoxics: fluorouracil, methotrexate, podophyllin.

45 [0031] Of particular interest are the forms for the transport and release of the above said substances and of biologically active substances such as proteins and their fragments, peptides, polynucleotides, growth factors, enzymes, vaccines, substances used in the treatment of diseases associated with genetic defects such as those depending on enzymatic hypo- or hyper-activity due to defects of the gene encoding for a given enzyme, deforming diseases and hereditary diseases.

50 [0032] The amide derivatives according to the present invention, in association with radioactive and non-radioactive substances, used in contrast systems, can be used as markers in *in vivo* diagnostics, for the identification and treatment of tumour tissues or damaged tissues.

55 [0033] One considerable advantage is represented by the possibility of processing the amide compounds and their salts in different forms of biomaterials such as sponges, films, membranes, threads, tampons, nonwoven fabric, microspheres, nanospheres, gauzes, gels and guide channels. Said biomaterials, used in one or more associated forms, may be constituted by one or more amide derivatives and their salts, optionally in association with other natural, synthetic or semisynthetic polymers, and optionally, with biologically active substances.

[0034] Some examples of natural polymers that can be used are collagen, coprecipitates of collagen and glycosaminoglycans, cellulose, polysaccharides in the form of gels such as chitin, chitosan, pectin or pectic acid, agar, agarose, xanthane, gellan, alginic acid or the alginates, polymannans or polyglycans, starch and natural gums.

5 [0035] Semisynthetic polymers, for example, can be chosen from the group consisting of collagen cross-linked with agents such as aldehydes or precursors of the same, dicarboxylic acids or their halogenides, diamines, derivatives of cellulose, hyaluronic acid, chitin or chitosan, gellan, xanthane, pectin or pectic acid, polyglycans, polymannan, agar, agarose, natural gum or glycosaminoglycans.

[0036] Lastly, examples of synthetic polymers that can be used are polylactic acid, polyglycolic acid or copolymers of the same or their derivatives, polydioxanes, polyphosphazenes, polysulphonic resin, polyurethanes, PTFE.

10 [0037] The above said biomaterials can be used to advantage in various fields of surgery, such as in internal and osteo-articular surgery, neuro-surgery, anastomotic, viscoelastic, ophthalmic, oncological, plastic and aesthetic, otorhinolaryngological, abdominal and pelvic, urogyneacological, cardiovascular surgery, in the prevention of post-surgical adhesions and hypertrophic scarring.

15 [0038] Moreover, the amide compounds in association with fibrin, and optionally other biologically active substances, can be used for the preparation of surgical glues.

[0039] The biomaterials according to the present invention can be used not only in the field of surgery but also in haemodialysis, cardiology, dermatology, ophthalmology, otorhinolaryngology, dentistry, orthopaedics, gynaecology, urology, in extra-corporeal blood circulation and oxygenation, in cosmetics and in angiology.

20 [0040] Said biomaterials, in their various forms, can be used to advantage as scaffolds on which to grow cells such as mesenchymal cells or mature cells to obtain connective, glandular and nerve tissue.

[0041] These biopolymers can also be used in the processes of coating objects used both in the medical field and in industrial sectors, giving new biological characteristics to the surfaces of the material used as a support.

25 [0042] Examples of the objects that can be coated are: catheters, guide channels, probes, cardiac valves, soft tissue prostheses, prostheses of animal origin such as cardiac valves from pigs, artificial tendons, bone and cardiovascular prostheses, contact lenses, blood oxygenators, artificial kidneys, hearts, pancreas, and livers, blood bags, syringes, surgical instruments, filtration systems, laboratory instruments, containers for cultures and for the regeneration of cells and tissues, supports for peptides, proteins and antibodies.

[0043] The process of coating the surface of such objects can be performed, for example by the Plasma Coating technique, described in the international patent application by the Applicant, publication No. WO96/24392.

30 [0044] The process for the preparation of amides on the nitrogen of hyaluronic acid or one of its deacetylated derivatives can be summarised as the following steps:

- deacetylation reaction, for example, by reaction with hydrazine sulphate (J. Riesenfeld, *Analy. Bloch.* 1990, vol. 188, pp 383-389);
- preparation of the quaternary ammonium salt of the deacetylated compound such as the tetrabutylammonium salt;
- preparation of the acylating agent in the form of an active ester, for example, of paranitrophenylester of aliphatic, aromatic, arylaliphatic, cycloaliphatic or heterocyclic acid, chosen for the formation of the amide;
- N-acylation reaction between the quaternary ammonium salt of hyaluronic acid or of one of its deacetylated derivatives and the acylating agent.

40 The compound is analytically characterised by the following methods:

- *analysis of the percentage of free amino groups:*  
the method described by J. Riesenfeld (*Analy. Bloch.* 1990, vol. 188, pp 383-389);
- *mean molecular weight:*  
this is determined by GPC using a set of Shadex B-803 and B-806 columns, and RI and MALLS equipment;
- *IR and UV spectroscopy analysis:*
- *TLC analysis.*

45 The sample is hydrolysed in a 1 mol. solution of sodium hydroxide for 2-4 hours at 70°C and then acidified with a 1 mol. solution of hydrochloric acid. The acid that is released during hydrolysis is extracted with organic solvent. The dry organic extract is analysed by HPLC.

- *% of N-acylation (hydrolysis of the amide)*  
two types of analysis are performed to measure the percentage of N-acylated groups:

- a) the method described by J. Riesenfeld (*Analy. Bloch.* 1990, vol. 188, pp 383-389);
- b) the sample is hydrolysed in a 1 mol. solution of sodium hydroxide for 2-4 hours at 70°C and then acidified with a 1 mol. solution of hydrochloric acid. The acid that is released during hydrolysis is extracted with organic solvent. The dry organic extract is analysed by HPLC.

[0045] Preparation of the amides on the carboxyl of hyaluronic acid or a derivative thereof consists in activating the carboxy groups by reaction of the same, in acid form or in the form of quaternary ammonium salt, with an agent such as carbonyldiimidazole, which converts carboxylic acid in the reactive form of an acylating agent.

[0046] Said reaction can be performed by catalysis with hydrochloric acid or acid resin and with an amine of the aliphatic, aromatic, arylaliphatic, cycloaliphatic and heterocyclic series.

[0047] Characterisation of the compounds includes the following methods:

- IR and UV spectroscopy;
- Chromatographic analysis.

[0048] The sample is hydrolysed in a 1 mol. solution of sodium hydroxide for 2-4 hours at 70°C and the amine that is released during hydrolysis is extracted with organic solvent. The dry organic extract is analysed by HPLC.

[0049] The percentage of amidation of the product is generally in the range of about 1% to about 90%, more preferably in the range of about 5% to about 60%, and most preferably in the range of about 20% to about 50%.

#### Example 1

##### Preparation of partially N-deacetylated hyaluronic acid in the form of sodium salt (DHA/Na)

[0050] One gram of sodium hyaluronate, with a mean molecular weight of 600 Kda, is solubilised in 50 ml of a 1% solution of hydrazine sulphate in hydrazine monohydrate.

[0051] This is left to react under agitation for five days (120 hours) at 55°C, after which the reaction is stopped by adding 100 ml of ethanol.

[0052] The precipitate thus formed is filtered through a Gooch crucible, washed with ethanol and then dried at room temperature at reduced pressure.

[0053] Any hydrazide of hyaluronic acid that will probably be formed during the reaction with hydrazinolysis is destroyed by reaction with  $\text{HIO}_3$  (iodic acid). As the reaction may be very vigorous, it is conducted while cooling the reaction container in iced water.

[0054] The product of hydrazinolysis is solubilised in 50 ml of a solution of 5% sodium acetate and reacted with 25 ml of a 0.5 M solution of iodic acid.

[0055] The reaction proceeds for 30 minutes under agitation, after which 5 ml of a 57% solution of  $\text{HI}$  is added to destroy any unreacted  $\text{HIO}_3$ .

[0056] The iodine that has formed is extracted from the aqueous solution with at least three 30-ml aliquots of ethyl ether (until complete decolouring of the aqueous phase). The aqueous solution is brought to neutral pH by adding a solution of  $\text{NaOH}$  0.5M followed by treatment with 100 ml of ethanol. The precipitate obtained is filtered with a Gooch crucible, washed with ethanol and then dried at room temperature and at reduced pressure.

[0057] The product obtained is characterised analytically to determine the percentage of N-deacetylated groups and the mean molecular weight.

40	Yield of the reaction % of N-deacetylation mean molecular weight	90% 26% 130 Kda
----	--	-----------------------

#### Example 2

##### Preparation of the salt of hyaluronic acid partially N-deacetylated with tetrabutylammonium (DHA/TBA).

[0058] One gram (2.5 mmol.) of hyaluronic acid sodium salt, partially N-deacetylated, is solubilised in 60 ml of water and the solution is percolated through a column filled with 25 ml of a sulphonic resin in the form of tetrabutylammonium salt (TBA). The sulphonic resin in  $\text{H}^+$  form is activated with a 40% solution w/v of  $\text{TBAOH}$ .

[0059] The eluate, containing N-deacetylated hyaluronic acid TBA salt is collected and freeze-dried.

#### Example 3

##### Preparation of p- $\text{NO}_2$ -phenylester of benzoic acid (acylating agent)

[0060] Ten grams (0.082 mol.) of benzoic acid is solubilised in 800 ml of  $\text{CH}_2\text{Cl}_2$ , after which 11.4 g (0.082 mol.) of

p-NO<sub>2</sub>-phenol and 16.9 g (0.082 mol) of DCC (Dicyclohexylcarbodiimide) are added. The reaction proceeds for 2 hours, while the solution is boiled and refluxed.

[0060] Subsequently, the dicyclohexylurea that forms is filtered and the filtered product is dried with a rotavapor under reduced pressure. The product thus obtained is purified by repeated crystallisation in ethyl acetate. The crystals are filtered and placed to dry at room temperature at reduced pressure.

[0061] The derivative is characterised by TLC analysis (eluent: CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate 90/10 and R<sub>f</sub>=0.77) and by IR and UV spectroscopy.

Yield of the reaction	92%
-----------------------	-----

10

#### Example 4

##### Preparation of p-NO<sub>2</sub>-phenylester of cinnamic acid (acylating agent)

[0062] Twelve grams (0.082 mol.) of cinnamic acid is solubilised in 800 ml of CH<sub>2</sub>Cl<sub>2</sub>, after which 11.4 g (0.082 mol.) of p-NO<sub>2</sub>-phenol and 16.9 g (0.082 mol) of DCC (Dicyclohexylcarbodiimide) are added. The reaction proceeds for 2 hours during which time the solution is boiled and refluxed.

[0063] Subsequently, the dicyclohexylurea is filtered and the filtered product is dried using a rotavapor at reduced pressure. The product obtained is purified by repeated crystallisation in ethanol, the crystals are filtered and left to dry at room temperature and reduced pressure.

[0064] The derivative is characterised by TLC analysis (eluent: CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate 90/10 and R<sub>f</sub>=0.77) and by IR and UV spectroscopy.

Yield of the reaction	89%
-----------------------	-----

25

#### Example 5

##### Preparation of p-NO<sub>2</sub>-phenylester of dodecanoic acid (acylating agent)

[0065] Sixteen grams of dodecanoic acid is solubilised in 1 litre of CH<sub>2</sub>Cl<sub>2</sub>, after which 11.4 g (0.082 mol.) of p-NO<sub>2</sub>-phenol and 16.9 g (0.082 mol) of DCC (Dicyclohexylcarbodiimide) are added. The reaction proceeds for 2 hours during which time the solution is boiled and refluxed.

[0066] Subsequently, the dicyclohexylurea is filtered and the filtered product is dried using a rotavapor at reduced pressure. The product obtained is purified by repeated crystallisation in ethyl acetate, the crystals are filtered and left to dry at room temperature and at reduced pressure.

[0067] The derivative is characterised by TLC analysis (eluent: CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate 90/10 and R<sub>f</sub> = 0.77) and by IR spectroscopy.

Yield of the reaction	93%
-----------------------	-----

40

#### Example 6

##### Preparation of p-NO<sub>2</sub>-phenylester of stearic acid (acylating agent)

[0068] 23.3 grams of stearic acid is solubilised in 1 litre of CH<sub>2</sub>Cl<sub>2</sub>, after which 11.4 g (0.082 mol.) of p-NO<sub>2</sub>-phenol and 16.9 g (0.082 mol) of DCC (Dicyclohexylcarbodiimide) are added. The reaction proceeds for 2 hours during which time the solution is boiled and refluxed.

[0069] Subsequently the dicyclohexylurea is filtered and the filtered product is dried using a rotavapor at reduced pressure. The product obtained is purified by repeated crystallisation in absolute ethanol, the crystals are filtered and left to dry at room temperature at reduced pressure.

[0070] The derivative is characterised by TLC analysis (eluent: CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate 90/10 and R<sub>f</sub> = 0.82) and by IR spectroscopy.

Yield of the reaction	87%
-----------------------	-----

55

**Example 7****Preparation of p-NO<sub>2</sub>-phenylester of o-acetyl salicylic acid (acylating agent)**

5 [0071] 14.7 g of acetylsalicylic acid is solubilised in 1 litre of CH<sub>2</sub>Cl<sub>2</sub>, after which 11.4 g (0.082 mol.) of p-NO<sub>2</sub>-phenol and 16.9 g (0.082 mol.) of DCC (Dicyclohexylcarbodiimide) are added. The reaction proceeds for 2 hours during which time the solution is boiled and refluxed.

10 [0072] Subsequently, the dicyclohexylurea that forms is filtered and the filtered product is dried using a rotavapor at reduced pressure. The product obtained is purified by repeated crystallisation in absolute ethanol, the crystals are filtered and left to dry at room temperature at reduced pressure.

15 [0073] The derivative is characterised by TLC analysis (eluent: CH<sub>2</sub>Cl<sub>2</sub>/ethyl acetate 90/10 and Rf-0.82) and by IR spectroscopy.

Yield of the reaction	80%
-----------------------	-----

15

**Example 8****Preparation of partially N-acylated hyaluronic acid (with the benzoic acid derivative)**

20 [0074] One gram (1.6 mmol.) of DHA/TBA (26% deacetylation) is solubilised in 50 ml of DMSO, after which 5 ml of a 10% solution of p-NO<sub>2</sub>-phenylester of benzoic acid (prepared according to example 3) in DMSO is added. The reaction proceeds for 24 hours, under agitation at room temperature, after which it is blocked by adding 2.5 ml of a saturated solution of NaCl. This is left to react for 30 minutes and then 100 ml of ethanol is slowly added. The precipitate thus obtained is filtered through a Gooch, washed with ethanol and ethyl ether and lastly dried at room temperature and at reduced pressure.

25 [0075] The derivative is analysed by TLC (after hydrolysis of the amide), colorimetric analysis of the percentage of free NH<sub>2</sub> groups and IR and UV spectroscopy.

Yield of the reaction	85%
% free NH <sub>2</sub>	11 %
% N-acylation	15%

30

**Example 9**

35

**Preparation of partially N-acylated hyaluronic acid (with the derivative of cinnamic acid)**

40 [0076] One gram (1.6 mmol.) of DHA/TBA (26% deacetylation) is solubilised in 50ml of NMP, after which 10 ml of a 10% solution of p-NO<sub>2</sub>-phenylester of cinnamic acid (prepared according to example 4) in NMP is added. The reaction proceeds for 24 hours, under agitation, at room temperature, after which it is blocked by adding 2.5 ml of a solution saturated with NaCl. This is left to react for 30 minutes and lastly 100 ml of ethanol is slowly added. The precipitate thus obtained is filtered through a Gooch crucible, washed with ethanol/water 9:1, ethyl ether and lastly dried at room temperature at reduced pressure.

45 [0077] The derivative is analysed by TLC (after hydrolysis of the amide), colorimetric analysis of the percentage of free NH<sub>2</sub> groups and IR and UV spectroscopic analysis.

Yield of the reaction	85%
% free NH <sub>2</sub>	11%
% N-acylation	15%

50

**Example 10****Preparation of partially N-acylated hyaluronic acid (with a derivative of dodecanoic acid)**

55

[0078] One gram (1.6 mmol.) of DHA/TBA (26% deacetylation) is solubilised in 50 ml of NMP, after which 3.2 ml of a 10% solution of p-NO<sub>2</sub>-phenylester of dodecanoic acid (prepared according to example 5) in NMP is added. The reaction proceeds for 24 hours, under agitation, at room temperature, after which it is blocked by adding 2.5 ml of a

saturated solution of NaCl. This is left to react for 30 minutes, after which 100 ml of ethanol is gently added. The precipitate obtained is filtered through a Gooch, washed with ethanol and ethyl ether and lastly dried at room temperature at reduced pressure.

[0079] The derivative is analysed by TLC (after hydrolysis of the amide), colorimetric analysis of the percentage of free NH<sub>2</sub> groups and IR and UV spectroscopy.

Yield of the reaction	88%
% free NH <sub>2</sub>	10%
% N-acylation	16%

10

### Example 11

#### Preparation of partially N-acylated hyaluronic acid (with the derivative of stearic acid)

[0080] One gram (1.6 mmol) of DHA/TBA (26% deacetylation) is solubilised in 50 ml of NMP, after which 6 ml of a 10% solution of p-NO<sub>2</sub>-phenylester of stearic acid (prepared according to example 6) in NMP is added. The reaction proceeds for 24 hours under agitation at room temperature after which it is blocked by adding 2.5 ml of a saturated solution of NaCl. This is left to react for 30 minutes and then 100 ml of ethanol is slowly added. The precipitate thus obtained is filtered through a Gooch filter, washed with ethanol and ethyl ether and lastly left to dry at room temperature and reduced pressure.

[0081] The derivative is analysed by TLC (after hydrolysis of the amide), colorimetric analysis of the percentage of free NH<sub>2</sub> groups and IR and UV spectroscopy.

Yield of the reaction	85%
% free NH <sub>2</sub>	12%
% N-acylation	14%

25

[0082] IR spectroscopy (Figure 1): the figure shows the difference between the IR spectrum of the amide and that of hyaluronic acid sodium salt. In the spectrum of the amide, there is an evident peak in the area of 2900 cm<sup>-1</sup>, due to the stretching of the CH<sub>2</sub> of the stearate.

### Example 12

#### Preparation of partially N-acylated hyaluronic acid (with acetyl salicylic acid derivative)

[0083] One gram (1.6 mmol.) of DHA/TBA is solubilised in 50 ml of NMP, after which 3.2 ml of a 10% solution of p-NO<sub>2</sub>-phenylester of acetyl salicylic acid (prepared according to example 7) in NMP is added. The reaction proceeds for 24 hours under agitation at room temperature, after which it is blocked by adding 2.5 ml of a saturated solution of NaCl. This is left to react for 30 minutes and lastly 100 ml of ethanol is slowly added. The precipitate thus obtained is filtered through a Gooch crucible, washed with ethanol and ethyl ether and then dried at room temperature and reduced pressure.

[0084] The derivative is analysed by TLC (after hydrolysis of the amide), colorimetric analysis of the percentage of free NH<sub>2</sub> groups and IR and UV spectroscopy.

Yield of the reaction	90%
% free NH <sub>2</sub>	10%
% N-acylation	16%

45

### Example 13

#### Preparation of benzylamide of hyaluronic acid

[0085] Two grams (3.2 mmol.) of tetrabutylammonium salt of hyaluronic acid (HA/TBA) is solubilised in 100 ml of DMSO. This solution is supplemented with 3 ml of humid acid resin in DMSO and 784 mg (4.8 mmol.) of 1,1-carbonyldiimidazole. This is left to react under agitation for 12 hours, after which it is filtered through a Gooch crucible to eliminate the resin and the filtered product is supplemented with 1 ml (9.6 mmol) of benzylamine. This is left to react

for 48 hours and then 5 ml of a saturated solution of NaCl is added and it is left under agitation for 30 minutes. It is supplemented with 200 ml of acetone and the precipitate thus obtained is filtered and dried at reduced pressure. The dry derivative is characterised by TLC, IR and HPLC analysis.

5

% of amidation	25%
----------------	-----

[0086] IR spectroscopy (Figures 2 and 3): the spectrum in figure 2 clearly shows a peak at 1537 cm<sup>-1</sup> due to bending in the NH plane (the amide band) and a peak at about 730 cm<sup>-1</sup> due to bending of the CH outside the plane of the aromatic ring. Figure 3 shows the difference between the graph relative to the amide and that of the sodium salt of hyaluronic acid.

10

#### Example 14

##### Preparation of benzylamide of hyaluronic acid

15

[0087] Two grams (3.2 mmol.) of tetrabutylammonium salt of hyaluronic acid (HA/TBA) is solubilised in 100 ml of DMSO. The solution is adjusted to pH 3 with HCl 1M and then 784 mg (4.8 mmol.) of 1,1-carbonyldiimidazole is added. This is left to react under agitation for 12 hours, then it is filtered through a Gooch crucible to eliminate the resin and 1 ml (9.6 mmol.) of benzylamine is added to the filtered product. This is left to react for 48 hours, then 5 ml of a saturated solution of NaCl is added and left under agitation for 30 minutes. To this is added 200 ml of acetone, the precipitate thus obtained is filtered and dried under reduced pressure.

20

[0088] The dry derivative is characterised by TLC, IR and HPLC analysis.

25

% amidation	15%
-------------	-----

#### Example 15

##### Preparation of benzylamide of hyaluronic acid

30

[0089] Two grams (5.2 mmol.) of hyaluronic acid in acid form is solubilised in 100 ml of DMF. To this solution is added 854 mg (5.2 mmol.) of 1,1-carbonyldiimidazole. This is left to react under agitation for 6 hours, after which 1.13 ml (10.4 mmol.) of benzylamine is added. The reaction proceeds for 48 hours, and is then blocked by adding 200 ml of acetone. The precipitate thus obtained is filtered and dried under reduced pressure.

35

[0090] The dry derivative is characterised by TLC, TR and HPLC analysis.

% amidation	60%
-------------	-----

#### Example 16

40

##### Preparation of benzylamide of hyaluronic acid

45

[0091] Two grams (5.2 mmol.) of hyaluronic acid in acid form is solubilised in 100 ml of DMF. To this solution is added 2 ml of pyridine, 3.68 g (0.026 mol.) of p-NO<sub>2</sub>-phenol and pyridine chloride until a pH of 7/8 is reached. Lastly, 5.3 (0.026 mol.) of DCC and 2.8 (0.026 mol.) of benzylamine are added. This is left to react under agitation for 16 hours after which the reaction is blocked by adding 200 ml of acetone. The precipitate thus obtained is filtered and dried under reduced pressure.

[0092] The dry derivative is characterised by TLC, IR and HPLC analysis.

50

% amidation	5%
-------------	----

#### Example 17

55

##### Preparation of benzylamide of hyaluronic acid

[0093] Two grams (3.2 mmol.) of HA/TBA is solubilised in 100 ml of DMSO. The solution is insufflated with gaseous HCl until the reaction mixture reaches a pH of between 4.5 and 5. Subsequently, 518 mg (3.2 mmol.) of carbonyldiim-

Idazole is added. It is left to react under agitation for one hour at room temperature, after which 0.700 ml (6.4 mmol.) of benzylamine is added. The reaction proceeds for 16-18 hours. After this time, 5 ml of a solution saturated with NaCl is added. It is precipitated by adding 200 ml of acetone and the precipitate thus obtained is filtered and dried under reduced pressure.

5 [0094] The dry derivative is characterised by TLC (after hydrolysis), IR and HPLC analysis.

% amidation	50%
-------------	-----

Example 18

10

**Preparation of the octylamide of hyaluronic acid**

15

[0095] Two grams (3.2 mmol.) of HA/TBA is solubilised in 100 ml of DMSO. The solution is insufflated with gaseous HCl till the reaction mixture reaches a pH of between 4.5 and 5. Subsequently, 207 mg (1.28 mmol.) of carbonyldiimidazole is added. It is left to react under agitation for one hour at room temperature, after which 0.417 ml (3.2 mmol.) of octylamine is added. The reaction proceeds for 16-18 hours. At the end of this time, 5 ml of a solution saturated with NaCl is added. It is precipitated by adding 200 ml of acetone and the precipitate obtained is filtered and dried under reduced pressure.

20

[0096] The dry derivative is characterised by TLC (after hydrolysis), IR and HPLC analysis.

% amidation	25%
-------------	-----

Example 19

25

**Preparation of the dodecyl amide of hyaluronic acid:**

30

[0097] Two grams (3.2 mmol.) of HA/TBA is solubilised in 100 ml of DMSO. The solution is insufflated with gaseous HCl till the reaction mixture reaches a pH of between 4.5 and 5. Subsequently, 104 mg (0.64 mmol.) of carbonyldiimidazole is added. It is left to react, under agitation, for one hour at room temperature, after which 600 mg (3.2 mmol.) of dodecylamine is added. The reaction proceeds for 16-18 hours. After this time, 5 ml of a solution saturated with NaCl is added. It is precipitated by adding 200 ml of acetone and the precipitate obtained is filtered and dried under reduced pressure.

[0098] The dry derivative is characterised by TLC (after hydrolysis), IR and HPLC analysis.

35

% amidation	15%
-------------	-----

Example 20

40

**Preparation of the hexadecylamide of hyaluronic acid:**

45

[0099] Two grams (3.2 mmol.) of HA/TBA is solubilised in 100 ml of DMSO. The solution is insufflated with gaseous HCl till the reaction mixture reaches a pH of between 4.5 and 5. Subsequently, 52 mg (0.32 mmol.) of carbonyldiimidazole is added and left to react under agitation for one hour at room temperature, after which 780 mg (3.2 mmol.) of hexadecylamine is added. The reaction proceeds for 16-18 hours. After this time, 5 ml of a solution saturated with NaCl is added. It is precipitated by adding 200 ml of acetone and the precipitate obtained is filtered and dried under reduced pressure.

[0100] The dry derivative is characterised by TLC (after hydrolysis), IR and HPLC analysis.

50


% amidation	5%
-------------	----

55

[0101] The invention being thus described, it is clear that these methods can be modified in various ways. Such modifications are not to be considered as divergences from the spirit and purpose of the invention and any modification that would appear evident to an expert in the field comes within the scope of the following claims:

## Claims

1. Amidic water-soluble compounds of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of the following general formula:



wherein:

R = NR<sub>6</sub>R<sub>7</sub>, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, OH, O-, alcoholic group of hyaluronic acid, amino group of deacylated hyaluronic acid;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, -CO-(CH<sub>2</sub>)<sub>2</sub>-COOY; Y = negative charge, or H;

R<sub>5</sub> = -CO-CH<sub>3</sub>, H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, acyl group of hyaluronic acid;

R<sub>6</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted;

R<sub>7</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted;

wherein at least one of R or R<sub>5</sub> forms an amide group, with the provisos that when R<sub>6</sub> is H, R<sub>7</sub> is not -CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, and that the amidic, water-soluble compound is not combined with a medicinal ingredient through an amide bond.

2. Amidic, water-soluble compounds of claim 1 obtained by reaction of the carboxylic groups of hyaluronic acid with an amino group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series for use in ophthalmology and in ophthalmic surgery.

3. Amidic compounds according to claim 1, wherein the hyaluronic acid derivatives are total or partial esters with aliphatic, aromatic, arylaliphatic, cycloaliphatic, heteroaliphatic alcohols.

4. Amidic compounds according to claim 1, wherein the hyaluronic acid derivatives are cross-linked compounds wherein part or all of the carboxy groups of the D-glucuronic residue form inner or inter-molecular esters with the alcoholic functions of the same polysaccharide chain or other chains respectively.

5. Amidic compounds according to claim 1, wherein the hyaluronic acid derivatives are cross-linked compounds wherein a part or all of the carboxy groups of the D-glucuronic residue are made to react with polyalcohols of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, generating cross-linking by means of spacer chains.

6. Amidic compounds according to claim 1, salified with heavy metals.

7. Amidic compounds according to claim 6, wherein the heavy metals are those of the 4<sup>th</sup>, 5<sup>th</sup> and 6<sup>th</sup> group of the table of elements and preferably silver, cobalt, iron, copper, zinc, arsenic, strontium, zirconium, antimony, gold, cesium, tungsten, selenium, platinum, ruthenium, bismuth, tin, titanium and mercury.

8. Amidic compounds according to claims 1-7, salified with pharmacologically active substances.

9. Amidic compounds according to claim 8, wherein the pharmacologically active substances are antibiotics, anti-

infective, antimicrobial, antiviral, cytostatic, antitumoral, anti-inflammatory, wound healing agents, anaesthetics, cholinergic or adrenergic agonists and antagonists, antithrombotic, anticoagulant, haemostatic, fibrinolytic, thrombolytic agents, proteins and their fragments, peptides, polynucleotides.


5 10 15 20 25 30 35 40 45 50 55

10. Amidic compounds and their salts according to claims 1-9, alone or in association with one another and/or with pharmacologically active substances for the preparation of pharmaceutical compositions.

11. Amidic compounds and their salts according to claim 10, wherein the pharmacologically active substances are antibiotics, anti-infective, antimicrobial, antiviral, cytostatic, antitumoral, anti-inflammatory, wound healing, anaesthetic agents, cholinergic or adrenergic agonists or antagonists, antithrombotic, anticoagulant, haemostatic, fibrinolytic, thrombolytic agents, proteins and their fragments, peptides, polynucleotides, growth factors, enzymes, vaccines, substances used in the treatment of diseases associated with genetic defects, deforming diseases and hereditary diseases.

12. Amidic compounds according to the previous claims, in association with radioactive or non-radioactive substances, used in contrast systems as labels in in vivo diagnostics to identify and treat tumoral tissues or damaged tissues.

13. Pharmaceutical compositions containing amidic water-soluble compounds of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of the following general formula:



wherein:

R = NR<sub>6</sub>R<sub>7</sub>, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, OH, O-, alcoholic group of hyaluronic acid, amino group of deacylated hyaluronic acid;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, -CO-(CH<sub>2</sub>)<sub>2</sub>-COOY; Y = negative charge, or H;


R<sub>5</sub> = -CO-CH<sub>3</sub>, H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, acyl group of hyaluronic acid;

R<sub>6</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted;

R<sub>7</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted;

wherein at least one of R or R<sub>5</sub> forms an amide group, alone or in association with one another or with other pharmacologically active substances and in association with a pharmaceutically acceptable carrier, with the proviso that the amidic water-soluble compound is not combined with a medicinal ingredient through an amide bond.

14. Biomaterials constituted by amidic water-soluble compounds of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of the following general formula:



5

10

wherein:

R = NR<sub>6</sub>R<sub>7</sub>, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, OH, O-, alcoholic group of hyaluronic acid, amino group of deacylated hyaluronic acid;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, -CO-(CH<sub>2</sub>)<sub>2</sub>-COY; Y = negative charge, or H;

R<sub>5</sub> = -CO-CH<sub>3</sub>, H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, acyl group of hyaluronic acid;

R<sub>6</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted;

R<sub>7</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted;

25

wherein at least one of R or R<sub>5</sub> forms an amide group, alone or in association with one another or with other natural, semisynthetic, synthetic polymers and, optionally, with biologically active substances, with the proviso that the amidic, water-soluble compound is not combined with a medicinal ingredient through an amide bond.

30

15. Biomaterials according to claim 14, wherein the natural polymers are collagen, coprecipitates of collagen and glycosaminoglycans, cellulose, polysaccharides in the form of gels such as chitin, chitosan, pectin or pectic acid, agar, agarose, xanthane, gellan, alginic acid or alginates, polymannans or polyglycans, starch, natural gums.

35

16. Biomaterials according to claim 14, wherein the semisynthetic polymers are collagen cross-linked with agents such as aldehydes or precursors of the same, dicarboxylic acids or their halogenides, diamines, derivatives of cellulose, hyaluronic acid, chitin or chitosan, gellan, xanthane, pectin or pectic acid, polyglycans, polymannan, agar, agarose, natural gum or glycosaminoglycans.

40

17. Biomaterials according to claim 14, wherein the synthetic polymers are polylactic acid, polyglycolic acid or copolymers of the same or their derivatives, polydioxanes, polyphosphazenes, polysulphonic resins, polyurethanes, PTFE.

45

18. Biomaterials according to claims 14-17, in association with fibrin, and optionally with other biologically active substances for the preparation of surgical glues.

19. Biomaterials according to claims 14-17 for the preparation of scaffolds for cell cultures.

20. Biomaterials according to claims 14-17 for the preparation of surgical and health-care articles.

50

21. Biomaterials according to claims 14-17, in the form of guide channels, gauzes, threads, gels, hydrogels, tampons, films, membranes, sponges, non-woven fabrics, microspheres, nanospheres and associations of the same.

22. Surgical and health-care articles according to claim 20, in the form of guide channels, gauzes, threads, gels, hydrogels, tampons, films, membranes, sponges, non-woven fabrics, microspheres, nanospheres.

55


23. Biomaterials according to claims 14-17 for use in surgery, haemodialysis, cardiology, dermatology, ophthalmology, ororhinolaryngology, dentistry, orthopaedics, gynaecology, urology, in extra-corporeal blood circulation and oxygenation, in cosmetics, in angiology.

24. Biomaterials according to claim 23 where surgery should be taken to mean internal or osteoarticular surgery, neurosurgery, anastomotic, viscoelastic, ophthalmic, oncological, plastic, aesthetic, otorhinolaryngological, abdominal-pelvic, urogynaecological or cardiovascular surgery, such as in the preparation of cardiac valves, vascular stents, in the prevention of post-surgical adhesions and hypertrophic scarring.

5 25. Amidic compounds and their salts according to claims 1-9 for the coating of biomedical objects such as bypasses, venous catheters, shunts, catheters, guide channels, probes, cardiac valves, artificial tendons, bone and cardiovascular prostheses, contact lenses, soft tissue prostheses, prostheses of animal origin, blood oxygenators, artificial kidneys, hearts, pancreas and livers, blood bags, syringes, surgical instruments, filtration systems, laboratory instruments, containers for cell cultures and for the regeneration of cells and tissues, supports for peptides, proteins, antibodies.

10 26. Use of the amidic compounds according to claims 7-8, in dermatology, ophthalmology, dentistry, stomatology, rheumatology, urology, gynaecology, internal surgery, as food supplements, anti-oxidant, anti-rheumatic, anti-tumoral, anti-inflammatory, analgesic, anti-ulcer agents.

15 27. Use of amidic water-soluble compounds of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of the following general formula:



30 wherein:

R = NR<sub>6</sub>R<sub>7</sub>, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, OH, O-, alcoholic group of hyaluronic acid, amino group of deacylated hyaluronic acid;

35 R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, -CO-(CH<sub>2</sub>)<sub>2</sub>-COOY; Y = negative charge, or H;

R<sub>5</sub> = -CO-CH<sub>3</sub>, H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, acyl group of hyaluronic acid;

40 R<sub>6</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted;


R<sub>7</sub> = is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted;

45 wherein at least one of R or R<sub>5</sub> forms an amide group

with the proviso that the amidic, water-soluble compound is not combined with a medicinal ingredient through an amide bond,

for the preparation of salts with pharmacologically active substances.

50 28. Use of amidic water-soluble compounds of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of the following general formula:



10

wherein:

R= NR<sub>6</sub>R<sub>7</sub>, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, OH, O-, alcoholic group of hyaluronic acid, amino group of deacylated hyaluronic acid;

15 R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>= H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, -CO-(CH<sub>2</sub>)<sub>2</sub>-COOY; Y = negative charge, or H;

R<sub>5</sub>= -CO-CH<sub>3</sub>, H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, acyl group of hyaluronic acid;

20 R<sub>6</sub>= is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted;


R<sub>7</sub>= is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted;

25

wherein at least one of R or R<sub>5</sub> forms an amide group alone or in association with one another and/or with pharmacologically active substances for the preparation of pharmaceutical compositions, biomaterials, surgical and health-care articles, slow release systems and systems for the coating of biomedical objects, with the proviso that the amidic, water-soluble compound is not combined with a medicinal ingredient through an amide bond.

30

29. Use of amidic water-soluble compounds of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of the following general formula:



40

wherein:

45 R= NR<sub>6</sub>R<sub>7</sub>, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, OH, O-, alcoholic group of hyaluronic acid, amino group of deacylated hyaluronic acid;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>= H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, -CO-(CH<sub>2</sub>)<sub>2</sub>-COOY; Y = negative charge, or H;

50 R<sub>5</sub>= -CO-CH<sub>3</sub>, H, SO<sub>3</sub><sup>-</sup>, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, acyl group of hyaluronic acid;

R<sub>6</sub>= is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted;

R<sub>7</sub>= is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted;

55

wherein at least one of R or R<sub>5</sub> forms an amide group in association with radioactive and non-radioactive substances, used in contrast systems as labels in in vivo diagnostics for the identification and treatment of tumoral

tissues or damaged tissues, with the proviso that the amidic, water-soluble compound is not combined with a medicinal ingredient through an amide bond.

5 30. Use of the amidic compounds and their salts according to claim 28, wherein the biomaterials are in the form of guide channels, gauzes, threads, gels, hydrogels, tampons, films, membranes, sponges, non-woven fabrics, microspheres, nanospheres and associations of the same.

10 31. Use of the amidic compound according to the previous claims, in surgery, haemodialysis, cardiology, dermatology, ophthalmology, otorhinolaryngology, dentistry, orthopaedics, gynaecology, urology, in extracorporeal blood circulation and oxygenation, in cosmetics and in angiology.

15 32. Use of the amide compounds according to claim 31, where surgery means internal, osteo-articular surgery, neurosurgery, anastomotic, viscoelastic, ophthalmic, oncological, plastic aesthetic, otorhinolaryngological, abdominal pelvic, urogynaecological, cardiovascular surgery such as in the preparation of cardiac valves, vascular stents, in the prevention of post-surgical adhesions and in hypertrophic scarring.

20 33. Use of biomaterials according to claims 14-17, in association with fibrin, and optionally with other biologically active substances for the preparation of surgical glues.

25 34. Use of biomaterials according to claims 14-17 for the preparation of scaffolds for cell cultures.

30 35. Process for the preparation of amides on the nitrogen of hyaluronic acid or a deacetylated derivative thereof involving the following steps:

- 25 a) deacetylation reaction;
- b) preparation of the quaternary ammonium salt of the deacetylated compound;
- c) preparation of the acylating agent in the form of active ester;
- d) N-acylation reaction between the quaternary ammonium salt of hyaluronic acid or a deacetylated derivative thereof and the acylating agent.

35 36. Process according to claim 35, wherein the deacetylation reaction is obtained by using hydrazine sulphate/hydrazine.

37. Process according to claim 35, wherein the quaternary ammonium salt is the tetrabutylammonium salt.

35 38. Process according to claim 35, wherein the active ester is the paranitrophenyl ester of aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic acid, chosen for the formation of the amide.


40 39. Process for the preparation of the amidic, water soluble compounds of claim 1 having the amides on the carboxyl of hyaluronic acid or a derivative thereof, involving the following steps:

- a) activation of the carboxy groups by reaction of the same, in the acid form or as a quaternary ammonium salt, with an activating agent, in acid solution or on acid resin;
- b) reaction with an amine of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series.

45 40. Process according to claim 39, wherein the activating agent is 1,1-carbonyldiimidazole.

#### Patentansprüche

50 1. Amidische, wasserlösliche Verbindungen von Hyaluronsäure oder einem Derivat davon, umfassend wenigstens eine Repetier-einheit der folgenden allgemeinen Formel:



5

10 worin:

R =  $\text{NR}_6\text{R}_7$  oder eine alkoholische Gruppe der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe, OH, O-, alkoholische Hyaluronsäuregruppe, Aminogruppe von deacylierter Hyaluronsäure;

15

$\text{R}_1, \text{R}_2, \text{R}_3, \text{R}_4$  = H,  $\text{SO}_3^-$ , Acylgruppe, die von einer Carbonsäure der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe stammt,  $-\text{CO}- (\text{CH}_2)_2\text{COOY}$ , Y = negative Ladung oder H;

20

$\text{R}_5$  =  $-\text{CO}-\text{CH}_3$ , H,  $\text{SO}_3^-$ , Acylgruppe, die von einer Carbonsäure der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe stammt, Acylgruppe von Hyaluronsäure;

25

$\text{R}_6$  = H oder eine aliphatische, aromatische, arylaliphatische, cycloaliphatische oder heterocyclische Gruppe, die substituiert oder unsubstituiert ist;

$\text{R}_7$  = H oder eine aliphatische, aromatische, arylaliphatische, cycloaliphatische oder heterocyclische Gruppe, die substituiert oder nicht substituiert ist;

30

wobei mindestens eines von R und  $\text{R}_5$  eine Amidgruppe bildet, mit den Maßgaben, dass, wenn  $\text{R}_6$  H ist,  $\text{R}_7$  nicht  $-\text{CH}_2\text{CO}_2\text{CH}_3$  ist, und dass die wasserlösliche, amidische Verbindung nicht über eine Amidbindung mit einem medizinischen Ingredienz verbunden ist.

35

2. Amidische, wasserlösliche Verbindungen nach Anspruch 1, die durch Reaktion der Carboxylgruppe von Hyaluronsäure mit einer Aminogruppe der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe erhalten werden, zur Verwendung in der Ophthalmologie und der Augenchirurgie.

40

3. Amidische Verbindungen nach Anspruch 1, wobei die Hyaluronsäurederivate vollständige oder Partialester mit aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heteroaliphatischen Alkoholen sind.

45

4. Amidische Verbindungen nach Anspruch 1, wobei die Hyaluronsäurederivate vernetzte Verbindungen sind, worin ein Teil der carboxygruppen des D-Glucuronsäurerests oder alle Carboxygruppen des D-Glucuronsäurerests intramolekulare Ester mit den alkoholischen Funktionen derselben Polysaccharidkette bzw. anderer Ketten bilden.

50

5. Amidische Verbindungen nach Anspruch 1, wobei die Hyaluronsäurederivate vernetzte Verbindungen sind, in denen ein Teil der Carboxygruppen des D-Glucuronsäurerests oder alle Carboxygruppen des D-Glucuronsäurerests mit Polyalkoholen der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe umgesetzt wurden, wodurch eine Vernetzung mittels Spacerketten erzeugt wurde.

55

6. Amidische Verbindungen nach Anspruch 1, die ein Salz mit Schwermetallen gebildet haben.

7. Amidische Verbindungen nach Anspruch 6, wobei die Schwermetalle solche der vierten, fünften und sechsten Gruppe des Periodensystems und vorzugsweise Silber, Kobalt, Eisen, Kupfer, Zink, Arsen, Strontium, Zirkonium, Antimon, Gold, Caesium, Wolfram, Selen, Platin, Ruthenium, Wismut, Zinn, Titan und Quecksilber sind.

8. Amidische Verbindungen nach den Ansprüchen 1 bis 7, die mit pharmakologisch aktiven Substanzen ein Salz gebildet haben.


9. Amidische Verbindungen nach Anspruch 8, wobei die biologisch aktiven Substanzen Antibiotika, Antiinfektiosa, antimikrobielle Mittel, antivirale Mittel, Cytostatika, Antitumormittel, antiinflammatorische Mittel, Wundheilungsmittel, Narkotika, cholinerge oder adrenerge Agonisten und Antagonisten, Mittel gegen Thrombose, Antikoagulantien, Hämostatika, fibrinolytische, thrombolytische Mittel, Proteine und deren Fragmente, Peptide, Nucleotide sind.

10. Amidische Verbindungen und ihre Salze nach den Ansprüchen 1 bis 9, allein oder in Verbindung miteinander und/oder mit pharmakologisch aktiven Substanzen zur Herstellung von pharmazeutischen Zusammensetzungen.

11. Amidische Verbindungen und ihre Salze nach Anspruch 10, wobei die pharmakologisch aktiven Substanzen Antibiotika, Antiinfektiosa, antimikrobielle Mittel, antivirale Mittel, Cytostatika, Antitumormittel, antiinflammatorische Mittel, Wundheilungsmittel, Narkotika, cholinerge oder adrenerge Agonisten oder Antagonisten, Mittel gegen Thrombose, Antikoagulantien, Hämostatika, fibrinolytische, thrombolytische Mittel, Proteine und deren Fragmente, Peptide, Polynukleotide, Wachstumsfaktoren, Enzyme, Vakzine, Substanzen, die bei der Behandlung von Krankheiten, assoziiert mit genetischen Defekten, Missbildungserkrankungen und Erbkrankheiten verwendet werden, sind.

12. Amidische Verbindungen nach den vorangehenden Ansprüchen in Verbindung mit radioaktiven oder nicht radioaktiven Substanzen, die in Kontratsystemen als Markierungen bei der in vivo-Diagnostik zur Identifizierung und Behandlung von Tumorgeweben oder geschädigten Geweben verwendet werden.

13. Pharmazeutische Zusammensetzungen, enthaltend amidische, wasserlösliche Verbindungen von Hyaluronsäure oder einem Derivat davon, umfassend wenigstens eine Repetiereinheit der folgenden allgemeinen Formel:



worin:

35  $R = NR_6R_7$  oder eine alkoholische Gruppe der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe, OH, O-, eine alkoholische Gruppe von Hyaluronsäure, eine Aminogruppe von deacylierter Hyaluronsäure;

40  $R_1, R_2, R_3, R_4 = H, SO_3^-$ , Acylgruppe, die von einer Carbonsäure der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe abgeleitet ist,  $-CO-(CH_2)_2-COOY$ , Y = negative Ladung oder H;

45  $R_5 = -CO-CH_3, H, SO_3^-$ , eine Acylgruppe, die von einer Carbonsäure der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe abgeleitet ist, eine acylgruppe von Hyaluronsäure;

50  $R_6 = H$  oder eine aliphatische, aromatische, arylaliphatische, cycloaliphatische oder heteroliphatische, cycloaliphatische oder heterocyclische Gruppe, die substituiert oder unsubstituiert ist;


55  $R_7 = H$  oder eine aliphatische, aromatische, arylaliphatische, cycloaliphatische oder heterocyclische Gruppe, die substituiert oder unsubstituiert ist;

wobei wenigstens einer von  $R$  und  $R_5$  eine Amlgruppe bildet, allein oder in Kombination miteinander oder mit anderen pharmakologisch aktiven Substanzen und in Kombination mit einem pharmazeutisch annehmbaren Träger, mit der Maßgabe, dass die amidische, wasserlösliche Verbindung nicht durch eine Amidbindung mit einem medizinischen Ingredienz verbunden ist.

14. Biomaterialien, gebildet durch amidische, wasserlösliche Verbindungen von Hyaluronsäure oder einem Derivat davon, umfassend wenigstens eine Repetiereinheit der folgenden allgemeinen Formel:

5

10



worin:

15 R = NR<sub>6</sub>R<sub>7</sub> oder eine alkoholische Gruppe der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe, OH, O-, eine alkoholische Gruppe von Hyaluronsäure, eine Aminogruppe von deacylierter Hyaluronsäure;

20 R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, SO<sub>3</sub><sup>-</sup>, Acylgruppe, die von einer Carbonsäure der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe abgeleitet ist, -CO- (CH<sub>2</sub>)<sub>2</sub>-COY, Y = negative Ladung oder H;

25 R<sub>5</sub> = -CO-CH<sub>3</sub>, H, SO<sub>3</sub><sup>-</sup>, eine Acylgruppe, die von einer Carbonsäure der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe abgeleitet ist, eine Acylgruppe von Hyaluronsäure;

30 R<sub>6</sub> = H oder eine aliphatische, aromatische, arylaliphatische, cycloaliphatische oder heterocyclische Gruppe, die subsbituiert oder unsubstituiert ist;

R<sub>7</sub> = H oder eine aliphatische, aromatische, arylaliphatische, cycloaliphatische oder heterocyclische Gruppe, die substituiert oder unsubstituiert ist;

wobei wenigstens eine von R und R<sub>5</sub> eine Amidgruppe bildet, alleine oder in Kombination Miteinander oder mit anderen natürlichen, halbsynthetischen, synthetischen Polymeren und gegebenenfalls mit biologisch aktiven Substanzen, mit der Maßgabe, dass die amidische, wasserlösliche Verbindung nicht durch eine Amidbindung mit einem medizinischen Ingredienz verbunden ist.

35

40

45

50

55

60

65

70

75

80

85

90

95

100

105

110

115

120

125

130

135

140

145

150

155

160

165

170

175

180

185

190

195

200

205

210

215

220

225

230

235

240

245

250

255

260

265

270

275

280

285

290

295

300

305

310

315

320

325

330

335

340

345

350

355

360

365

370

375

380

385

390

395

400

405

410

415

420

425

430

435

440

445

450

455

460

465

470

475

480

485

490

495

500

505

510

515

520

525

530

535

540

545

550

555

560

565

570

575

580

585

590

595

600

605

610

615

620

625

630

635

640

645

650

655

660

665

670

675

680

685

690

695

700

705

710

715

720

725

730

735

740

745

750

755

760

765

770

775

780

785

790

795

800

805

810

815

820

825

830

835

840

845

850

855

860

865

870

875

880

885

890

895

900

905

910

915

920

925

930

935

940

945

950

955

960

965

970

975

980

985

990

995

1000

1005

1010

1015

1020

1025

1030

1035

1040

1045

1050

1055

1060

1065

1070

1075

1080

1085

1090

1095

1100

1105

1110

1115

1120

1125

1130

1135

1140

1145

1150

1155

1160

1165

1170

1175

1180

1185

1190

1195

1200

1205

1210

1215

1220

1225

1230

1235

1240

1245

1250

1255

1260

1265

1270

1275

1280

1285

1290

1295

1300

1305

1310

1315

1320

1325

1330

1335

1340

1345

1350

1355

1360

1365

1370

1375

1380

1385

1390

1395

1400

1405

1410

1415

1420

1425

1430

1435

1440

1445

1450

1455

1460

1465

1470

1475

1480

1485

1490

1495

1500

1505

1510

1515

1520

1525

1530

1535

1540

1545

1550

1555

1560

1565

1570

1575

1580

1585

1590

1595

1600

1605

1610

1615

1620

1625

1630

1635

1640

1645

1650

1655

1660

1665

1670

1675

1680

1685

1690

1695

1700

1705

1710

1715

1720

1725

1730

1735

1740

1745

1750

1755

1760

1765

1770

1775

1780

1785

1790

1795

1800

1805

1810

1815

1820

1825

1830

1835

1840

1845

1850

1855

1860

1865

1870

1875

1880

1885

1890

1895

1900

1905

1910

1915

1920

1925

1930

1935

1940

1945

1950

1955

1960

1965

1970

1975

1980

1985

1990

1995

2000

2005

2010

2015

2020

2025

2030

2035

2040

2045

2050

2055

2060

2065

2070

2075

2080

2085

2090

2095

2100

2105

2110

2115

2120

2125

2130

2135

2140

2145

2150

2155

2160

2165

2170

2175

2180

2185

2190

2195

2200

2205

2210

2215

2220

2225

2230

2235

2240

2245

2250

2255

2260

2265

2270

2275

2280

2285

2290

2295

2300

2305

2310

2315

2320

2325

2330

2335

2340

2345

2350

2355

2360

2365

2370

2375

2380

2385

2390

2395

2400

2405

2410

2415

2420

2425

2430

2435

2440

2445

2450

2455

2460

2465

2470

2475

2480

2485

2490

2495

2500

2505

2510

2515

2520

2525

2530

2535

2540

2545

2550

2555

2560

2565

2570

2575

2580

2585

2590

2595

2600

2605

2610

2615

2620

2625

2630

2635

2640

2645

2650

2655

2660

2665

2670

2675

2680

2685

2690

2695

2700

2705

2710

2715

2720

2725

2730

2735

2740

2745

2750

2755

2760

2765

2770

2775

2780

2785

2790

2795

2800

2805

2810

2815

2820

2825

2830

2835

2840

2845

2850

2855

2860

2865

2870

2875

2880

2885

2890

2895

2900

2905

2910

2915

2920

2925

2930

2935

2940

2945

2950

2955

2960

2965

2970

2975

2980

2985

2990

2995

3000

3005

3010

3015

3020

3025

3030

3035

3040

3045

3050

3055

3060

3065

3070

3075

3080

3085

3090

3095

3100

3105

3110

3115

3120

3125

3130

3135

3140

3145

3150

3155

3160

3165

3170

3175

3180

3185

3190

3195

3200

3205

3210

3215

3220

3225

3230

3235

3240

3245

3250

3255

3260

3265

3270

3275

3280

3285

3290

3295

3300

3305

3310

3315

3320

3325

3330

3335

3340

3345

3350

3355

3360

3365

3370

3375

3380

3385

3390

3395

3400

3405

3410

3415

3420

3425

3430

3435

3440

3445

3450

3455

3460

3465

3470

3475

3480

3485

3490

3495

3500

3505

3510

3515

3520

3525

3530

3535

3540

3545

3550

3555

3560

3565

3570

3575

3580

3585

3590

3595

3600

3605

3610

3615

3620

3625

3630

3635

3640

3645

3650

3655

3660

3665

3670

3675

3680

3685

3690

3695

3700

3705

3710

3715

3720

3725

3730

3735

3740

3745

3750

3755

3760

3765

3770

3775

3780

3785

3790

3795

3800

3805

3810

3815

3820

3825

3830

3835

3840

3845

3850

3855

3860

3865

3870

3875

3880

3885

3890

3895

3900

3905

3910

3915

3920

3925

3930

3935

3940

3945

3950

3955

3960

3965

3970

3975

3980

3985

3990

3995

4000

4005

4010

4015

4020

4025

4030

4035

4040

4045

4050

4055

4060

4065

4070

4075

4080

4085

4090

4095

4100

4105

4110

4115

4120

4125

4130

4135

4140

4145

4150

4155

4160

4165

4170

4175

4180

4185

4190

4195

4200

4205

4210

4215

4220

4225

4230

4235

4240

4245

4250

4255

4260

4265

4270

4275

4280

4285

4290

4295

4300

4305

4310

4315

4320

4325

4330

4335

4340

4345

4350

4355

4360

4365

4370

4375

4380

4385

4390

4395

4400

4405

4410

4415

4420

4425

4430

4435

4440

4445

4450

4455

4460

4465

4470

4475

4480

4485

4490

4495

4500

4505

4510

4515

4520

4525

4530

4535

4540

4545

4550

4555

4560

4565

4570

4575

4580

4585

4590

4595

4600

4605

4610

4615

4620

4625

4630

4635

4640

4645

4650

4655

4660

4665

4670

4675

4680

4685

4690

4695

4700

4705

4710

4715

4720

4725

4730

4735

4740

4745

4750

4755

4760

4765

4770

4775

4780

4785

4790

4795

4800

4805

4810

4815

4820

4825

4830

4835

4840

4845

4850

4855

4860

4865

4870

4875

4880

4885

4890

4895

4900

4905

4910

4915

4920

4925

4930

4935

4940

4945

4950

4955

4960

4965

4970

4975

4980

4985

4990

4995

5000

5005

5010

5015

5020

5025

5030

5035

5040

5045

5050

5055

5060

5065

5070

5075

5080

5085

5090

5095

5100

5105

5110

5115

5120

5125

5130

5135

5140

5145

5150

5155

5160

5165

5170

5175

5180

5185

5190

5195

5200

5205

5210

5215

5220

5225

5230

5235

5240

5245

5250

5255

5260

5265

5270

5275

5280

5285

5290

5295

5300

5305

5310

5315

5320

5325

5330

5335

5340

5345

5350

5355

5360

5365

5370

5375

5380

5385

5390

5395

5400

5405

5410

5415

5420

5425

5430

5435

5440

5445

5450

5455

5460

5465

5470

5475

5480

5485

5490

5495

5500

5505

5510

5515

5520

5525

5530

5535

5540

5545

5550

5555

5560

5565

5570

5575

5580

5585

5590

5595

5600

5605

5610

5615

5620

5625

5630

5635

5640

5645

5650

5655

5660

5665

5670

5675

5680

5685

5690

5695

5700

5705

5710

5715

5720

5725

5730

5735

5740

5745

5750

5755

5760

5765

5770

5775

5780

5785

5790

5795

5800

5805

5810

5815

5820

5825

5830

5835

5840

5845

5850

5855

5860

5865

5870

5875

5880

5885

5890

5895

5900

5905

5910

5915

5920

21. Biomaterialien nach den Ansprüchen 14 bis 17 in Form von Führungskanälen, Gaze, Fäden, Gelen, Hydrogelen, Tampons, Filmen, Membranen, Schwämmen, Faservliesen, Mikrokügelchen, Nanokügelchen und Kombinationen derselben.

5 22. Chirurgische Gegenstände und Gegenstände zur Besundheitsfürsorge nach Anspruch 20 in Form von Führungskanälen, Gaze, Fäden, Gelen, Hydrogelen, Tampons, Filmen, Membranen, Schwämmen, Faservliesen, Mikrokügelchen, Nanokügelchen.


10 23. Biomaterialien nach den Ansprüchen 14 bis 17 zur Verwendung in der Chirurgie, Hämodialyse, Kardiologie, Dermatologie, Ophthalmologie, Otorhinolaryngologie, Zahnheilkunde, Orthopädie, Gynäkologie, Urologie, beim extrakorporalen Blutkreislauf und der extrakorporalen Oxygenation, in der Kosmetik und der Angiologie.

15 24. Biomaterialien nach Anspruch 23, wobei Chirurgie bezeichneten soll: innere und osteoartikuläre Chirurgie, Neurochirurgie, Anastomosenchirurgie, viskoelastische, ophthalmische, onkologische, plastische, ästhetische; otorhinolaryngologische Chirurgie, Abdomen-Becken-Chirurgie, urogynäkologische oder kardiovaskuläre Chirurgie, zum Beispiel bei der Herstellung von Herzklappen, Gefäßstents, bei der Prävention von Adhäsionen nach Operation und der hypertrophen Vernarbung.

20 25. Amidische Verbindungen und ihre Salze nach den Ansprüchen 1 bis 9 für die Beschiebung biomedizinischer Objekte wie Bypässe, Venenkatheter, Shunts, Katheter, Führungskanäle, Sonden, Merzklappen; künstliche Sehnen, Knochen- und kardiovaskuläre Prothesen, Kontaktlinsen, Bindegewebsprothesen, Prothesen tierischen Ursprungs, Blutoxygenatoren, künstliche Nieren, Herzen, Pankreas und Leber, Blutbeutel, Spritzen, chirurgische Instrumente, Filtrationssysteme, Laborinstrumente, Behälter für Zellkulturen und für die Regeneration von Zellen und Geweben, Träger für Peptide, Proteine, Antikörper.

25 26. Verwendung der amidischen Verbindungen nach den Ansprüchen 7 bis 8 in der Dermatologie, Ophthalmologie, Zahnheilkunde, Stomatologie, Rheumatologie, Urologie, Gynäkologie, inneren Chirurgie, als Nahrungsmittelergänzungen, Antioxidanz, Antirheumatikum, Antitumormittel, antiinflammatorisches Mittel, Analgetikum, Mittel gegen Ulcus.

30 27. Verwendung von amidischen, wasserlöslichen Verbindungen von Hyaluronsäure oder einem Derivat davon, umfassend die wenigstens eine Repetieeinheit der folgenden allgemeinen Formel:



worin:

45 R = NR<sub>6</sub>R<sub>7</sub> oder eine alkoholische Gruppe der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe, OH, O-, eine alkoholische Gruppe von Hyaluronsäure, eine Aminogruppe von deacylierter Hyaluronsäure;

50 R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, SO<sub>3</sub><sup>-</sup>, Acylgruppe, die von einer Carbonsäure der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe abgeleitet ist, -CO- (CH<sub>2</sub>)<sub>2</sub>-COOY, Y = negative Ladung oder H;


55 R<sub>5</sub> = -CO-CH<sub>3</sub>, H, SO<sub>3</sub><sup>-</sup>, eine Acylgruppe, die von einer Carbonsäure der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe abgeleitet ist, eine Acylgruppe von Myaluronsäure;

R<sub>6</sub> = H oder eine aliphatische, aromatische, acylaliphatische, cycloaliphatische oder heterocyclische Gruppe, die substituiert oder unsubstituiert ist;

$R_7$  = H oder eine aliphatische, aromatische, arylaliphatische, cycloaliphatische oder heterocyclische Gruppe, die substituiert oder unsubstituiert ist;

wobei wenigstens einer von R und R<sub>3</sub> eine Amidgruppe bildet,  
mit der Maßgabe, dass die amidische, wasserlösliche Verbindung nicht über eine Amidbindung mit einem medi-  
zinischen Ingredienz kombiniert ist,  
zur Herstellung von Salzen mit pharmakologisch aktiven Substanzen.

28. Verwendung von amidischen, wasserlöslichen Verbindungen von Hyaluronsäure oder einem Derivat davon, umfassend wenigstens eine Repetiereinheit der folgenden allgemeinen Formel:



worin:

R = NR<sub>6</sub>R<sub>7</sub> oder eine alkoholische Gruppe der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe, OH, O-, eine alkoholische Gruppe von Hyaluronsäure, eine Aminogruppe von deacylierter Hyaluronsäure;

$R_1, R_2, R_3, R_4 =$  H,  $SO_3^-$ , Acylgruppe, die von einer carboxylsäure der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe abgeleitet ist,  $-CO-(CH_2)_2-COOY$ , Y = negative Ladung oder H;

**R<sub>5</sub>** = -CO-CH<sub>3</sub>, H, SO<sub>3</sub>-, eine Acylgruppe, die von einer Carbonsäure der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe abgeleitet ist, eine Acylgruppe von Hyaluronsäure;


**R<sub>6</sub>** = H oder eine aliphatische, aromatische, arylaliphatische, cycloaliphatische oder heterocyclische Gruppe, die substituiert oder unsubstituiert ist;

$R_7$  = H oder eine aliphatische, aromatische, arylaliphatische, cycloaliphatische oder heterocyclische Gruppe, die substituiert oder unsubstituiert ist;

wobei wenigstens einer von R und R<sub>5</sub> eine Amingruppe bildet, allein oder in Kombination miteinander und/oder mit pharmakologisch aktiven Substanzen zur Herstellung von

Gesundheitsfürsorge, Systemen mit langsamer Freisetzung und Systeme für die Beschichtung biomedizinischer Gegenstände, mit der Maßgabe, dass die wasserlösliche amidische Verbindung nicht über eine Amidbindung mit einem medizinischen Ingredienz verbunden ist.

29. Verwendung von amidischen, wasserlöslichen Verbindungen von Hyaluronsäure oder einem Derivat davon, umfassend wenigstens eine Repetiereinheit der folgenden allgemeinen Formel:



worin:

5 R = NR<sub>6</sub>R<sub>7</sub> oder eine alkoholische Gruppe der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe, OH, O-, eine alkoholische Gruppe von Hyaluronsäure, eine Amynogruppe von deacylierter Hyaluronsäure;

10 R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, SO<sub>3</sub>-, Acylgruppe, die von einer Carbonsäure der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe abgeleitet ist, -CO- (CH<sub>2</sub>)<sub>2</sub>-COOY, Y = negative Ladung oder H;

15 R<sub>5</sub> = -CO-CH<sub>3</sub>, H, SO<sub>3</sub>-, eine Acylgruppe, die von einer Carbonsäure der aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe abgeleitet ist, eine Acylgruppe von Hyaluronsäure;

20 R<sub>6</sub> = H oder eine aliphatische, aromatische, arylaliphatische, cycloaliphatische oder heterocyclische Gruppe, die substituiert oder unsubstituiert ist;

R<sub>7</sub> = H oder eine aliphatische, aromatische, arylaliphatische, cycloaliphatische oder heterocyclische Gruppe, die substituiert oder unsubstituiert ist;

25 wobei wenigstens einer von R und R<sub>5</sub> eine Amidgruppe bildet, in Kombination mit radioaktiven und nicht radioaktiven Substanzen, die in Kontrastsystemen als Markierungen bei der in vivo-Diagnostik zur Identifizierung und Behandlung von Tumor-geweben oder geschädigten Geweben verwendet werden, mit der Maßgabe, dass die amidische, wasserlösliche Verbindung nicht über eine Amidbindung mit einem modizinischen Ingredienz kombiniert ist:

30 30. Verwendung der amidischen Verbindungen und ihrer Salze nach Anspruch 28, wobei die Biomaterialien in Form von Führungskanälen, Gazen, Fäden, Gelen, Hydrogelen, Tampons, Filman, Membranen, Schwämmen, Faservliesen, Mikrokügelchen, Nanokügelchen und Kombination derselben vorliegen.

35 31. Verwendung der amidischen Verbindung nach den vorangehenden Ansprüchen in der Chirurgie, Hämodialyse, Kardiologie, Dermatologie, Ophthalmologie, Otorhinolaryngologie, Zahnmedizin, Orthopädie, Gynäkologie, Urologie, im extrakorporalen Blutkreislauf und bei der extrakorporalen Oxygenation, in Kosmetika und in der Angiologie.

40 32. Verwendung der Amidverbindungen nach Anspruch 31, wobei die Chirurgie bedeutet innere Chirurgie, osteoartikuläre Chirurgie, Neurochirurgie, Anastomosenchirurgie, viskoelastische, ophthalmische, onkologische, plastisch-ästhetische, otorhinolaryngologische Chirurgie, Abdomen-Becken-Chirurgie, urogynäkologische, kardiovaskuläre Chirurgie, zum Beispiel bei der Herstellung von Herzklappen, Gefäßstents, bei der Prävention von Adhäsionen nach Chirurgie und bei hypertropher Vernarbung.

45 33. Verwendung von Biomaterialien nach den Ansprüchen 14 bis 17 in Verbindung mit Fibrin und gegebenenfalls mit anderen biologisch aktiven Substanzen zur Herstellung von chirurgischen Leimen.

34. Verwendung von Biomaterialien nach den Ansprüchen 14 bis 17 zur Herstellung von Gerüsten für Zellkulturen.

50 35. Verfahren zur Herstellung von Amiden am Stickstoff von Hyaluronsäure oder einem deacetylierten Derivat davon, umfassend die folgenden Schritte:

- a) Deacetylierungsreaktion;
- b) Herstellung des quaternären Ammoniumsalzes der deacetylierten Verbindung;
- c) Herstellung des Acylierungsgenzen in Form eines aktiven Esters;
- d) N-Acylierungsreaktion zwischen dem quaternären Ammoniumsalz von Hyaluronsäure oder einem deacetylierten Derivat davon und dem Acylierungsmittel.

55 36. Verfahren nach Anspruch 35, wobei die Deacetylierungsreaktion durch Verwendung von Hydrazinsulfat/Hydrazin erreicht wird.

37. Verfahren nach Anspruch 35, wobei das quaternäre Ammoniumsalz das Tetrabutylammoniumsalz ist.

38. Verfahren nach Anspruch 35, wobei der aktive Ester der Parantrophenylester einer aliphatischen, aromatischen, arylaliphatischen, cycloaliphatischen, heterocyclischen Säure, die zur Bildung des Amids ausgewählt wurde, ist.

39. Verfahren zur Herstellung der amidischén, wasserlöslichen Verbindungen nach Anspruch 1, die die Amide an der Carboxylgruppe von Hyaluronsäure oder einem Derivat davon umfassen, umfassend die folgenden Schritte:


10 a) Aktivierung der Carboxygruppe durch Reaktion derselben in der Säureform oder als quaternäres Ammoniumsalz mit einem Aktivierungsmittel in saurer Lösung oder an einem sauren Harz;

b) Reaktion mit einem Amin der aliphatischen, aromatischen arylaliphatischen, cycloaliphatischen, heterocyclischen Reihe.

40. Verfahren nach Anspruch 39, wobei das Aktivierungsmittel 1,1-Carbonyldiimidazol ist.

15 Revendications

20 1. Composés amidiques hydrosolubles de l'acide hyaluronique ou d'un dérivé de celui-ci comprenant au moins une unité de répétition de formule générale suivante :



dans laquelle :

35  $R = NR_6R_7$ , où un groupe alcoolique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, OH, O-, un groupe alcoolique de l'acide hyaluronique, un groupe amino de l'acide hyaluronique désacylé ;

40  $R_1, R_2, R_3, R_4 = H, SO_3^-$ , un groupe acyle dérivé d'un acide carboxylique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique,  $-CO-(CH_2)_2-COOY$ ; Y = charge négative, ou H ;

$R_5 = -CO-CH_3, H, SO_3^-$ , un groupe acyle dérivé d'un acide carboxylique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, un groupe acylique de l'acide hyaluronique ;

45  $R_6 = H$  ou un groupe aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, substitué ou non substitué ;

$R_7 = H$  ou un groupe aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, substitué ou non substitué ;

dans laquelle au moins l'un parmi R ou  $R_5$  forme un groupe amide, à condition que lorsque  $R_6$  est H,  $R_7$  n'est pas  $-CH_2CO_2CH_3$ , et que le composé amidique hydrosoluble ne soit pas combiné avec un ingrédient médical par l'intermédiaire d'une liaison amide.

50 2. Composés amidiques hydrosolubles obtenus par réaction des groupes carboxyliques de l'acide hyaluronique avec un groupe amino de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique destinés à être utilisés en ophtalmologie et en chirurgie ophtalmique.

55 3. Composés amidiques selon la revendication 1, dans lesquels les dérivés de l'acide hyaluronique sont des esters totaux ou partiels avec des alcools aliphatiques, aromatiques, arylaliphatiques, cycloaliphatiques ou hétéroaliphatiques.

4. Composés amidiques selon la revendication 1, dans lesquels les dérivés de l'acide hyaluronique sont des composés réticulés dans lesquels une partie ou tous les groupes carboxy du résidu D-glucuronique forment des esters intra ou intermoléculaires avec les fonctions alcooliques de la même chaîne polysaccharidique ou d'autres chaînes respectivement.

5. Composés amidiques selon la revendication 1, dans lesquels les dérivés de l'acide hyaluronique sont des composés réticulés dans lesquels une partie ou tous les groupes carboxy du résidu D-glucuronique sont tels qu'ils réagissent avec des polyalcools de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, générant une réticulation à l'aide de chaînes espaces.

10. Composés amidiques selon la revendication 1, transformés en sels avec des métaux lourds.

15. Composés amidiques selon la revendication 6, dans lesquels les métaux lourds sont ceux du 4<sup>ème</sup>, 5<sup>ème</sup> et 6<sup>ème</sup> groupe du tableau de classification des éléments et de préférence l'argent, le cobalt, le fer, le cuivre, le zinc, l'arsenic, le strontium, le zirconium, l'antimoine, l'or, le césum, le tungstène, le sélénium, le platine, le ruthénium, le bismuth, l'étain, le titane et le mercure.

20. Composés amidiques selon les revendications 1 à 7, transformés en sels avec des substances pharmacologiquement actives.


25. Composés amidiques selon la revendication 8, dans lesquels les substances pharmacologiquement actives sont des antibiotiques, des anti-infectieux, des antimicrobiens, des antiviraux, des cytostatiques, des antitumoraux, des anti-inflammatoires, des agents de cicatrisation des blessures, des anesthésiques, des agonistes et des antagonistes cholinergiques ou adrénnergiques, des antithrombiques, des anticoagulants, des hémostatiques, des fibrinolytiques, des thrombolytiques, des protéines et leurs fragments, des peptides, des polynucléotides.

30. Composés amidiques et leurs sels selon les revendications 1 à 9, seuls ou en association les uns avec les autres et/ou avec des substances pharmacologiquement actives pour la préparation de compositions pharmaceutiques.

35. Composés amidiques et leurs sels selon la revendication 10, dans lesquels les substances pharmacologiquement actives sont des antibiotiques, des anti-infectieux, des antimicrobiens, des antiviraux, des cytostatiques, des antitumoraux, des anti-inflammatoires, des agents de cicatrisation des blessures, des anesthésiques, des agonistes ou des antagonistes cholinergiques ou adrénnergiques, des antithrombiques, des anticoagulants, des hémostatiques, des fibrinolytiques, des thrombolytiques, des protéines et leurs fragments, des peptides, des polynucléotides, des facteurs de croissance, des enzymes, des vaccins, des substances utilisées dans le traitement des maladies associées à des défauts génétiques, des maladies déformantes et des maladies héréditaires.

40. Composés amidiques selon les revendications précédentes, en association avec des substances radioactives ou non radioactives, utilisés dans des systèmes de contraste en tant que marqueurs pour le diagnostic *in vivo* afin d'identifier et de traiter des tissus tumoraux ou des tissus endommagés.

45. Compositions pharmaceutiques contenant des composés amidiques hydrosolubles de l'acide hyaluronique ou d'un dérivé de celui-ci comprenant au moins une unité de répétition de formule générale suivante :



55. dans laquelle :

R = NR<sub>6</sub>R<sub>7</sub>, ou un groupe alcoolique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, OH, O-, un groupe alcoolique de l'acide hyaluronique, un groupe amino de l'acide hyaluronique

désacylé ;

5  $R_1, R_2, R_3, R_4 = H, SO_3^-$ , un groupe acyle dérivé d'un acide carboxylique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique,  $-CO-(CH_2)_2-COOY$ ;  $Y =$  charge négative, ou  $H$  ;

$R_5 = -CO-CH_3, H, SO_3^-$ , un groupe acyle dérivé d'un acide carboxylique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, un groupe acylique de l'acide hyaluronique ;

10  $R_6 = H$  ou un groupe aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, substitué ou non substitué ;

$R_7 = H$  ou un groupe aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, substitué ou non substitué ;

10


dans laquelle au moins un parmi  $R$  ou  $R_5$  forme un groupe amide, seuls ou en association les uns avec les autres ou avec d'autres substances pharmacologiquement actives et en association avec un support pharmaceutiquement acceptable, à condition que le composé amidique hydrosoluble ne soit pas combiné avec un ingrédient médicinal par l'intermédiaire d'une liaison amide.

15

14. Biomatériaux à base de composés amidiques hydrosolubles de l'acide hyaluronique ou d'un dérivé de celui-ci comprenant au moins une unité de répétition de formule générale suivante :

20

25



dans laquelle :

30

$R = NR_6R_7$ , ou un groupe alcoolique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique,  $OH, O-$ , un groupe alcoolique de l'acide hyaluronique, un groupe amino de l'acide hyaluronique désacylé ;

35

$R_1, R_2, R_3, R_4 = H, SO_3^-$ , un groupe acyle dérivé d'un acide carboxylique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique,  $-CO-(CH_2)_2-COOY$ ;  $Y =$  charge négative, ou  $H$  ;

$R_5 = -CO-CH_3, H, SO_3^-$ , un groupe acyle dérivé d'un acide carboxylique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, un groupe acylique de l'acide hyaluronique ;

40

$R_6 = H$  ou un groupe aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, substitué ou non substitué ;

$R_7 = H$  ou un groupe aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, substitué ou non substitué ;

45

dans laquelle au moins un parmi  $R$  ou  $R_5$  forme un groupe amide, seuls ou en association les uns avec les autres ou avec d'autres polymères naturels, semisynthétiques, synthétiques et, éventuellement, avec des substances biologiquement actives, à condition que le composé amidique hydrosoluble ne soit pas combiné avec un ingrédient médicinal par l'intermédiaire d'une liaison amide.

50

15. Biomatériaux selon la revendication 14, dans lesquels les polymères naturels sont le collagène, les coprécipités de collagène et de glycosaminoglycanes, la cellulose, les polysaccharides sous forme de gels tels que la chitine, le chitosan, la pectine ou l'acide pectique, l'agar, l'agarose, le xanthane, le gellane, l'acide alginique ou les alginates, les polymannanes ou les polyglycanes, l'amidon, les gommes naturelles.

55

16. Biomatériaux selon la revendication 14, dans lesquels les polymères semisynthétiques sont le collagène réticulé avec des agents tels que des aldéhydes ou des précurseurs d'aldéhydes, des acides dicarboxyliques ou leurs halogénures, des diamines, des dérivés de cellulose, l'acide hyaluronique, la chitine ou le chitosan, le gellane, le xanthane, la pectine ou l'acide pectique, les polyglycanes, les polymannanes, l'agar, l'agarose, la gomme naturelle ou les glycosaminoglycanes.

17. Biomatériaux selon la revendication 14, dans lesquels les polymères synthétiques sont l'acide polylactique, l'acide polyglycolique ou les copolymères de l'acide polyglycolique ou leurs dérivés, les polydioxanes, les polyphosphazènes, les résines polysulphoniques, les polyuréthanes, le PTFE.

5 18. Biomatériaux selon les revendications 14 à 17, en association avec la fibrine, et éventuellement avec d'autres substances biologiquement actives pour la préparation de colles chirurgicales.

19. Biomatériaux selon les revendications 14 à 17 pour la préparation d'échafaudages pour des cultures cellulaires.

10 20. Biomatériaux selon les revendications 14 à 17 pour la préparation d'articles chirurgicaux et de soins de santé.

21. Biomatériaux selon les revendications 14 à 17, sous forme de canaux de guidage, de gazes, de fils, de gels, d'hydrogels, de tampons, de films, de membranes, d'éponges, de tissus non-tissés, de microsphères, de nanosphères et associations de ceux-ci.

15 22. Articles chirurgicaux et de soins de santé selon la revendication 20, sous la forme des canaux de guidage, de gazes, de fils, de gels, d'hydrogels, de tampons, de films, de membranes, d'éponges, de tissus non-tissés, de microsphères ou de nanosphères.


23. Biomatériaux selon les revendications 14 à 17 destinés à être utilisés en chirurgie, en hémodialyse, en cardiologie, en dermatologie, en ophtalmologie, en oto-rhino-laryngologie, en dentisterie, en orthopédie, en gynécologie, en urologie, dans le domaine de la circulation sanguine extra corporelle et l'oxygénation, en cosmétique ou en angiologie.

25 24. Biomatériaux selon la revendication 23 dans lesquels la chirurgie sous-entend la chirurgie interne ou ostéoarticulaire, la neurochirurgie, la chirurgie anastomotique, viscoélastique, ophtalmique, oncologique, plastique, esthétique, oto-rhino-laryngologique, abdomino-pelvienne, uro-gynécologique ou cardiovasculaire, telle que dans la préparation de valves cardiaques, d'endoprothèses vasculaires, dans la prévention des adhérences postchirurgicales et de la cicatrisation hypertrophique.

30 25. Composés amidiques et leurs sels selon les revendications 1 à 9 destinés au revêtement des objets biomédicaux tels que des déviations, des cathéters veineux, des anostomoses « shunts », des cathéters, des canaux de guidage, des sondes, des valves cardiaques, des tendons artificiels, des prothèses osseuses et cardiovasculaires, des lentilles de contact, des prothèses de tissu mou, des prothèses d'origine animale, des oxygénateurs de sang, des reins, des coeurs, des pancréas et des foies artificiels, des sacs sanguins, des seringues, des instruments chirurgicaux, des systèmes de filtration, des instruments de laboratoire, des récipients pour les cultures cellulaires et pour la régénération des cellules et des tissus, des supports pour les peptides, les protéines, les anticorps.

35 26. Utilisation des composés amidiques selon les revendications 7 à 8, en dermatologie, en ophtalmologie, en dentisterie, en stomatologie, en rhumatologie, en urologie, en gynécologie, en chirurgie interne, en tant que suppléments alimentaires, agents antioxydants, anti-rhumatismaux, anti-tumoraux, anti-inflammatoires, analgésiques ou anti-ulcéreux.

40 27. Utilisation des composés amidiques hydrosolubles de l'acide hyaluronique ou d'un dérivé de celui-ci comprenant au moins une unité de répétition de formule générale suivante :



dans laquelle :

R = NR<sub>6</sub>R<sub>7</sub>, ou un groupe alcoolique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou

hétérocyclique, OH, O-, un groupe alcoolique de l'acide hyaluronique, un groupe amino de l'acide hyaluronique désacylé ;

5 R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, SO<sub>3</sub><sup>-</sup>, un groupe acyle dérivé d'un acide carboxylique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, -CO-(CH<sub>2</sub>)<sub>2</sub>-COOY ; Y = charge négative, ou H ;


R<sub>5</sub> = -CO-CH<sub>3</sub>, H, SO<sub>3</sub><sup>-</sup>, un groupe acyle dérivé d'un acide carboxylique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, un groupe acylique de l'acide hyaluronique ;

R<sub>6</sub> = H ou un groupe aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, substitué ou non substitué ;

10 R<sub>7</sub> = H ou un groupe aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, substitué ou non substitué ;

dans laquelle au moins l'un parmi R ou R<sub>5</sub> forme un groupe amide, à condition que le composé amidique hydrosoluble ne soit pas combiné avec un ingrédient médicinal par l'intermédiaire d'une liaison amide, 15 pour la préparation de sels avec des substances pharmacologiquement actives.

28. Utilisation des composés amidiques hydrosolubles de l'acide hyaluronique ou d'un dérivé de celui-ci comprenant au moins une unité de répétition de formule générale suivante :



30 dans laquelle :

R = NR<sub>6</sub>R<sub>7</sub>, ou un groupe alcoolique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, OH, O-, un groupe alcoolique de l'acide hyaluronique, un groupe amino de l'acide hyaluronique désacylé ;

35 R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> = H, SO<sub>3</sub><sup>-</sup>, un groupe acyle dérivé d'un acide carboxylique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, -CO-(CH<sub>2</sub>)<sub>2</sub>-COOY ; Y = charge négative, ou H ;


R<sub>5</sub> = -CO-CH<sub>3</sub>, H, SO<sub>3</sub><sup>-</sup>, un groupe acyle dérivé d'un acide carboxylique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, un groupe acylique de l'acide hyaluronique ;

R<sub>6</sub> = H ou un groupe aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, substitué ou non substitué ;

40 R<sub>7</sub> = H ou un groupe aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, substitué ou non substitué ;

dans laquelle au moins l'un parmi R ou R<sub>5</sub> forme un groupe amide, seuls ou en association les uns avec les autres et/ou avec des substances pharmaceutiquement actives pour la préparation de compositions pharmaceutiques, de biomatériaux, d'articles chirurgicaux et de soins de santé, de systèmes à libération lente et de systèmes destinés au revêtement des objets biomédicaux, à condition que le composé amidique hydrosoluble ne soit pas combiné avec un ingrédient médicinal par l'intermédiaire d'une liaison amide.

29. Utilisation des composés amidiques hydrosolubles de l'acide hyaluronique ou d'un dérivé de celui-ci comprenant au moins une unité de répétition de formule générale suivante :



5

10

dans laquelle :

15  $R = NR_6R_7$ , ou un groupe alcoolique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique,  $OH, O^-$ , un groupe alcoolique de l'acide hyaluronique, un groupe amino de l'acide hyaluronique désacétylé ;

20  $R_1, R_2, R_3, R_4 = H, SO_3^-$ , un groupe acyle dérivé d'un acide carboxylique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique,  $-CO-(CH_2)_2-COOY$  ;  $Y = charge négative$ , ou  $H$  ;

25  $R_5 = -CO-CH_3, H, SO_3^-$ , un groupe acyle dérivé d'un acide carboxylique de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, un groupe acylique de l'acide hyaluronique ;

30  $R_6 = H$  ou un groupe aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, substitué ou non substitué ;

35  $R_7 = H$  ou un groupe aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, substitué ou non substitué ;

40 dans laquelle au moins l'un parmi  $R$  ou  $R_5$  forme un groupe amide, en association avec des substances radioactives et non radioactives, utilisés dans des systèmes de contraste en tant que marqueurs pour le diagnostic *in vivo* afin d'identifier et de traiter des tissus tumoraux ou des tissus endommagés, à condition que le composé amidique hydro soluble ne soit pas combiné avec un ingrédient médicinal par l'intermédiaire d'une liaison amide.

45 30. Utilisation des composés amidiques et de leurs sels selon la revendication 28, dans laquelle les biomatériaux sont sous forme de canaux de guidage, de gazes, de fils, de gels, d'hydrogels, de tampons, de films, de membranes, d'éponges, de tissus non tissés, de microsphères, de nanosphères et associations de ceux-ci.

50 31. Utilisation du composé amidique selon les revendications précédentes, en chirurgie, en hémodialyse, en cardiologie, en dermatologie, en ophtalmologie, en oto-rhino-laryngologie, en dentisterie, en orthopédie, en gynécologie, en urologie, dans le domaine de la circulation sanguine extra corporelle et l'oxygénation, en cosmétique ou en angiologie.

55 32. Utilisation des composés amidiques selon la revendication 31, où la chirurgie sous-entend la chirurgie interne ou ostéoarticulaire, la neurochirurgie, la chirurgie anastomotique, viscoélastique, ophtalmique, oncologique, plastique, esthétique, oto-rhino-laryngologique, abdomino-pelvienne, uro-gynécologique, cardiovasculaire, telle que dans la préparation de valves cardiaques, d'endoprothèses vasculaires, dans la prévention d'adhésions postchirurgicales et de la cicatrisation hypertrophique.

33. Utilisation des biomatériaux selon les revendications 14 à 17, en association avec la fibrine, et éventuellement avec d'autres substances biologiquement actives pour la préparation de colles chirurgicales.

34. Utilisation des biomatériaux selon les revendications 14 à 17 pour la préparation d'échafaudages pour des cultures cellulaires.

35. Procédé de préparation d'amides sur l'azote de l'acide hyaluronique ou d'un dérivé désacétylé de celui-ci mettant en jeu les étapes suivantes :

a) réaction de désacétylation ;

b) préparation du sel d'ammonium quaternaire du composé désacétylé ;

c) préparation de l'agent d'acylation sous forme d'un ester actif ;

d) réaction de N-acylation entre le sel d'ammonium quaternaire de l'acide hyaluronique ou un dérivé désacétylé de celui-ci et l'agent d'acylation.

36. Procédé selon la revendication 35, dans lequel la réaction de desacétylation est obtenue en utilisant un mélange sulphate d'hydrazine/hydrazine.

5 37. Procédé selon la revendication 35, dans lequel le sel d'ammonium quaternaire est le sel de tétrabutylammonium.

38. Procédé selon la revendication 35, dans lequel l'ester actif est l'ester paranitrophénylique d'un acide aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique, choisi pour la formation de l'amide.

10 39. Procédé de préparation des composés amidiques hydrosolubles selon la revendication 1 ayant les amides sur le carboxyle de l'acide hyaluronique ou d'un dérivé de celui-ci, mettant en jeu les étapes suivantes :

15 a) activation des groupes carboxy par réaction de ceux-ci, sous la forme acide ou d'un sel d'ammonium quaternaire, avec un agent d'activation, dans une solution acide ou sur une résine acide ;

b) réaction avec une amine de la série aliphatique, aromatique, arylaliphatique, cycloaliphatique ou hétérocyclique.

20 40. Procédé selon la revendication 39, dans lequel l'agent d'activation est le 1,1-carbonyldiimidazole.

25

30

35


40

45

50

55

Fig. 1  
hyaluronic acid sodium salt







Fig. 3



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**